RGNX

Latest SEC Filings & News for RGNX

1 most recent filing and news item mentioning RGNX. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/RGNX/news?limit=20"

Pull RGNX filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

RegulatoryJun 29, 2026Positive

Regenerxbio dosed first patient in sura-vec trial for diabetic retinopathy.

Regenerxbio announced the first patient dosed in the NAAVIGATE trial and received a $100 million milestone payment from AbbVie. This milestone highlights progress in potential one-time gene therapies for diabetic retinopathy, aiming to reduce vision loss.

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.